Dr. Tibor J. Kovacsovics, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 38
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
OR license MD24797
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- City of Hope Cancer Center Phoenix Goodyear, AZ
Medical groups
- City of Hope Medical Group of Arizona LLC (160 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 38
- Services billed
- 224
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 47 | 12 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 29 | 11 |
| Established patient office or other outpatient visit, 30-39 minutes | 22 | 21 |
| Established patient office or other outpatient visit, 40-54 minutes | 19 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Portland, OR | 27 |
| Levofloxacin Other prescribers in Portland, OR | 20 |
| Fluconazole Other prescribers in Portland, OR | 15 |
| Venclexta (venetoclax) | 14 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Portland, OR | 13 |
| Allopurinol Other prescribers in Portland, OR | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 29 payments worth $9,836 in total to this clinician.
| Amgen Inc. | $3,489 |
|---|---|
| Stemline Therapeutics Inc. | $2,730 |
| Syndax Pharmaceuticals, Inc. | $2,673 |
| Kite Pharma, Inc. | $157 |
| Celgene Corporation | $156 |
| Janssen Research & Development, LLC | $146 |
| GlaxoSmithKline, LLC. | $142 |
| AstraZeneca Pharmaceuticals LP | $135 |
| Consulting Fee | $7,047 |
|---|---|
| Food and Beverage | $1,552 |
| Travel and Lodging | $1,238 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Stemline Therapeutics Inc. May 2, 2025 | Consulting Fee ELZONRIS · Oncology | $2,730 |
| Syndax Pharmaceuticals, Inc. Dec 5, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $2,259 |
| Amgen Inc. Jun 10, 2025 | Consulting Fee BLINCYTO · Oncology | $2,058 |
| Amgen Inc. May 28, 2025 | Travel and Lodging BLINCYTO · Oncology · travel to Chicago, IL · in-kind | $681 |
| Amgen Inc. May 29, 2025 | Travel and Lodging BLINCYTO · Oncology · travel to CHICAGO, IL · in-kind | $345 |
| Amgen Inc. May 29, 2025 | Travel and Lodging BLINCYTO · Oncology · travel to CHICAGO, IL · in-kind | $182 |
| Syndax Pharmaceuticals, Inc. Dec 5, 2025 | Travel and Lodging REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to ORLANDO, FL | $30.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $9,370 in research payments for these studies, mostly to the institutions running them.
- A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Beone Medicines USA, Inc. · Recruiting · NCT05006716 - Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Daiichi Sankyo Inc. · Active, not recruiting · NCT06578247
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.